GLSI vs. PBYI, ETTX, MITO, STOK, WVE, LBPH, PLRX, PAHC, TNGX, and GHRS
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Puma Biotechnology (PBYI), Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), Stoke Therapeutics (STOK), Wave Life Sciences (WVE), Longboard Pharmaceuticals (LBPH), Pliant Therapeutics (PLRX), Phibro Animal Health (PAHC), Tango Therapeutics (TNGX), and GH Research (GHRS). These companies are all part of the "medical" sector.
Puma Biotechnology (NASDAQ:PBYI) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
Puma Biotechnology received 531 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 37.50% of users gave Greenwich LifeSciences an outperform vote.
Puma Biotechnology has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of 0.00%. Greenwich LifeSciences' return on equity of 35.49% beat Puma Biotechnology's return on equity.
Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 81.82%. Greenwich LifeSciences has a consensus price target of $36.00, indicating a potential upside of 142.75%. Given Puma Biotechnology's higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Puma Biotechnology.
In the previous week, Greenwich LifeSciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for Greenwich LifeSciences and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.06 beat Greenwich LifeSciences' score of 0.96 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Summary
Puma Biotechnology beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
